drugset / Trial / NCT00649818

Fasting Study of Lorazepam Tablets 2 mg and Ativan Tablets 2 mg

NCT00649818

Phase 1 Completed 28 enrolled Mylan Pharmaceuticals Inc
RandomizedCrossoverOpen-labelOther

Summary

The objective of this study was to investigate the bioequivalence of Mylan's lorazepam 2 mg tablets to Wyeth's Ativan 2 mg tablets following a single, oral 2 mg (1 x 2 mg) dose administered under fasting conditions.

Timeline

Start
2004-12
Primary completion
2004-12
Completion
2004-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Lorazepam Small molecule 2 mg Oral

Indications

No indication recorded.